Roche Defends HER2 Franchise After MARIANNE Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.